Recent studies have demonstrated that the STING agonist DMXAA suppresses HBV replication and transcription by stimulating STING signaling, thereby attenuating the progression of liver fibrosis and liver injury (70). The gene discussed is STING1; the disease is Hepatic fibrosis.